Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Ostrominski JW, et al. Among authors: pitt b. J Card Fail. 2024 Sep;30(9):1170-1174. doi: 10.1016/j.cardfail.2024.04.015. Epub 2024 May 11. J Card Fail. 2024. PMID: 38740173 Free article. Clinical Trial. No abstract available.
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).
Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Böhm M, Gimpelewicz C, Botha J, Moores S, Lewis EF, Rattunde H, Maggioni A; ASTRONAUT investigators and study coordinators. Gheorghiade M, et al. Eur J Heart Fail. 2011 Jan;13(1):100-6. doi: 10.1093/eurjhf/hfq209. Epub 2010 Nov 30. Eur J Heart Fail. 2011. PMID: 21123186 Free article. Clinical Trial.
Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA; TOPCAT Investigators. Lewis EF, et al. Among authors: pitt ba. Circ Heart Fail. 2016 Mar;9(3):e001937. doi: 10.1161/CIRCHEARTFAILURE.114.001937. Circ Heart Fail. 2016. PMID: 26962133 Clinical Trial.
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B; SOLOIST-WHF committees and investigators. Szarek M, et al. Among authors: pitt b. Ann Intern Med. 2021 Aug;174(8):1065-1072. doi: 10.7326/M21-0651. Epub 2021 Jun 22. Ann Intern Med. 2021. PMID: 34152828 Clinical Trial.
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F. Ferreira JP, et al. Among authors: pitt b. Eur J Heart Fail. 2023 Jan;25(1):108-113. doi: 10.1002/ejhf.2726. Epub 2022 Nov 9. Eur J Heart Fail. 2023. PMID: 36303266 Free article.
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Ferreira JP, Cleland JG, Girerd N, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, González A, Diez J, Solomon SD, Claggett B, Pfeffer MA, Pitt B, Petutschnigg J, Pieske B, Edelmann F, Zannad F. Ferreira JP, et al. Among authors: pitt b. Int J Cardiol. 2023 Apr 15;377:86-88. doi: 10.1016/j.ijcard.2023.01.088. Epub 2023 Feb 2. Int J Cardiol. 2023. PMID: 36738846 Free article.
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C, Bansilal S, Gebel M, Joseph A, Lawatscheck R, Bakris GL. Agarwal R, et al. Among authors: pitt b. JAMA Cardiol. 2023 Aug 1;8(8):732-741. doi: 10.1001/jamacardio.2023.1505. JAMA Cardiol. 2023. PMID: 37314801 Free PMC article.
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Monzo L, Girerd N, Duarte K, Ferreira JP, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Pitt B, Zannad F. Monzo L, et al. Among authors: pitt b. Eur J Heart Fail. 2023 Aug;25(8):1444-1449. doi: 10.1002/ejhf.2952. Epub 2023 Jul 7. Eur J Heart Fail. 2023. PMID: 37370197 Free article. Clinical Trial.
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
Matsumoto S, Kondo T, Yang M, Campbell RT, Docherty KF, de Boer RA, Desai AS, Lam CSP, Packer M, Pitt B, Rouleau JL, Vaduganathan M, Zannad F, Zile MR, Solomon SD, Jhund PS, McMurray JJV. Matsumoto S, et al. Among authors: pitt b. Eur J Heart Fail. 2023 Dec;25(12):2202-2214. doi: 10.1002/ejhf.3044. Epub 2023 Oct 5. Eur J Heart Fail. 2023. PMID: 37771260 Free article.
1,247 results